Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.52 |
| ▸ | LATS1 | O95835 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.40 |
| ▸ | PRKCG | P05129 | 2/20 | 0.40 |
| ▸ | PRKCB | P05771 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 2/20 | 0.40 |
| ▸ | PRKACA | P17612 | 2/20 | 0.40 |
| ▸ | PRKACG | P22612 | 2/20 | 0.40 |
| ▸ | PRKACB | P22694 | 2/20 | 0.40 |
| ▸ | PRKCH | P24723 | 2/20 | 0.40 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38663101 | 1.00 | GSK3B (0.52) | GSK3BLATS1ADRB2NCF1PLD1 | |
| SCHEMBL5461889 | 1.00 | GSK3B (0.52) | GSK3BLATS1ADRB2NCF1PLD1 | |
| Hydrochloric Acid SCHEMBL30619012 | 0.98 | GSK3B (0.51) | GSK3BLATS1ADRB2NCF1PLD1 | |
| SCHEMBL17884836 | 0.82 | SLC6A2 (0.57) | ROCK1RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL17884678 | 0.82 | SLC6A2 (0.57) | ROCK1RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL1028438 | 0.82 | SLC6A2 (0.57) | ROCK1RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL30952103 | 0.82 | LATS1 (0.43) | GSK3BLATS1ROCK1RAD52HTR2C | |
| SCHEMBL7446422 | 0.81 | LATS1 (0.54) | GSK3BLATS1ROCK1RAD52HTR2C | |
| SCHEMBL17884780 | 0.81 | CHRNB2 (0.55) | LATS1ROCK1HTR2CHTR2AHTR2B | |
| SCHEMBL5464361 | 0.81 | CHRNB2 (0.55) | LATS1ROCK1HTR2CHTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GSK3B 351/4885LATS1 939/4885ADRB2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.